Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Multiple Myeloma 4Lymphoma, Large B-Cell, Diffuse 2Recurrence 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Neoplasms 1Lymphoma, Mantle-Cell 1Lymphoma, B-Cell, Marginal Zone 1Locally Recurrent Skin Squamous Cell Carcinoma 1Leukemia, Plasma Cell 1Endometrial Neoplasms 1Classic Follicular Lymphoma 1Carcinoma, Non-Small-Cell Lung 1

Interventions

pembrolizumab 28Paclitaxel 24Carboplatin 19Bevacizumab 14Specimen Handling 13Magnetic Resonance Spectroscopy 10Doxorubicin 8Cisplatin 8Biopsy 8olaparib 7lenvatinib 7Taxes 7Letrozole 7Megestrol Acetate 6Fulvestrant 6durvalumab 5dostarlimab 5Nivolumab 5Medroxyprogesterone Acetate 5Gemcitabine 5trastuzumab deruxtecan 4abemaciclib 4X-Rays 4Trastuzumab 4Tirzepatide 4Progestins 4Oxaliplatin 4Immunoglobulin G 4Fluorouracil 4Docetaxel 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Endometrial Neoplasms × Hyaluronoglucosaminidase × 90 days × Clear all
NCT05256225 2026-06-03

Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma

National Cancer Institute (NCI)

Phase 3 Recruiting
360 enrolled
Gynecologic

Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡